Geographic Expansion Opportunity to target regions where FebriDx is already commercialized (Australia, Canada, Europe, Gulf Cooperation Countries, Saudi Arabia, Singapore, UK) and explore FDA clearance pathways or partnerships to accelerate U.S. entry.

Antibiotic Stewardship Position FebriDx as a frontline triage tool to reduce unnecessary antibiotic prescriptions in acute respiratory infections, aligning with global antimicrobial resistance initiatives and payer-supported value propositions.

Clinical Adoption Leverage rapid 15-minute results and fingerstick sampling to engage primary care networks, urgent care centers, and community clinics seeking point-of-care solutions that improve visit throughput and patient flow.

Partnership Opportunities Capitalize on past collaboration with Atomo Diagnostics to pursue joint development or distribution agreements, expanding test variants or companion diagnostics for febrile respiratory illnesses.

Growth Readiness Target mid-market healthcare systems and regional distributors with revenue in the upper millions to low billions, highlighting the scalable POC model, cost-effectiveness, and strong negative predictive value as a differentiator.